JP2020527144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527144A5 JP2020527144A5 JP2020501379A JP2020501379A JP2020527144A5 JP 2020527144 A5 JP2020527144 A5 JP 2020527144A5 JP 2020501379 A JP2020501379 A JP 2020501379A JP 2020501379 A JP2020501379 A JP 2020501379A JP 2020527144 A5 JP2020527144 A5 JP 2020527144A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- siglec
- seq
- variable region
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 13
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 7
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims 6
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims 6
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 102000045929 human SIGLEC9 Human genes 0.000 claims 5
- 210000000822 natural killer cell Anatomy 0.000 claims 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000056982 human CD33 Human genes 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 3
- 101150069255 KLRC1 gene Proteins 0.000 claims 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims 1
- 102100027093 Sialic acid-binding Ig-like lectin 12 Human genes 0.000 claims 1
- 101710143288 Sialic acid-binding Ig-like lectin 12 Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000002784 cytotoxicity assay Methods 0.000 claims 1
- 231100000263 cytotoxicity test Toxicity 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000057310 human KLRC1 Human genes 0.000 claims 1
- 102000050701 human SIGLEC7 Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530454P | 2017-07-10 | 2017-07-10 | |
| US62/530,454 | 2017-07-10 | ||
| PCT/EP2018/068532 WO2019011852A1 (en) | 2017-07-10 | 2018-07-09 | POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527144A JP2020527144A (ja) | 2020-09-03 |
| JP2020527144A5 true JP2020527144A5 (https=) | 2021-04-30 |
Family
ID=62981177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501379A Pending JP2020527144A (ja) | 2017-07-10 | 2018-07-09 | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11447545B2 (https=) |
| EP (1) | EP3652207A1 (https=) |
| JP (1) | JP2020527144A (https=) |
| KR (1) | KR20200026254A (https=) |
| CN (1) | CN111465614A (https=) |
| AU (1) | AU2018298673A1 (https=) |
| BR (1) | BR112019027353A2 (https=) |
| CA (1) | CA3066571A1 (https=) |
| WO (1) | WO2019011852A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| AU2018298676A1 (en) | 2017-07-10 | 2019-12-19 | Innate Pharma | Siglec-9-neutralizing antibodies |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| AU2020304139A1 (en) * | 2019-06-28 | 2022-02-24 | Crage Medical Co., Limited | Cell for resisting transplant reaction and method |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US11987612B2 (en) | 2019-11-04 | 2024-05-21 | Alector Llc | Siglec-9 ECD fusion molecules |
| US20230009582A1 (en) * | 2019-11-14 | 2023-01-12 | Memo Therapeutics Ag | Anti-siglec-9 antibody molecules |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| EP4257153B1 (en) * | 2020-12-04 | 2025-11-12 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1307826B1 (it) | 1999-12-16 | 2001-11-19 | Dipartimento Di Medicina Speri | Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| CN101484471B (zh) | 2006-06-30 | 2013-11-06 | 诺沃-诺迪斯克有限公司 | 抗-nkg2a抗体及其用途 |
| US8187801B2 (en) * | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
| ES2751549T3 (es) | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP2812027A1 (en) * | 2012-02-07 | 2014-12-17 | Innate Pharma | Mica binding agents |
| JP2017532025A (ja) | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| SMT202000562T1 (it) * | 2014-09-16 | 2020-11-10 | Innate Pharma | Neutralizzazionne delle vie inibitorie nei linfociti |
| CA2959463A1 (en) * | 2014-09-16 | 2016-03-24 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| WO2017123745A1 (en) * | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| WO2017153433A1 (en) * | 2016-03-08 | 2017-09-14 | Innate Pharma | Siglec neutralizing antibodies |
| JP7137563B2 (ja) * | 2016-08-05 | 2022-09-14 | アラコス，インコーポレイティド | がん治療用の抗Ｓｉｇｌｅｃ－７抗体 |
| AU2018298676A1 (en) | 2017-07-10 | 2019-12-19 | Innate Pharma | Siglec-9-neutralizing antibodies |
| KR20220061977A (ko) * | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| CN114555123B (zh) * | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20230065974A (ko) * | 2020-09-10 | 2023-05-12 | 퓨리노미아 바이오테크, 아이엔씨. | NTPDase3의 표적화를 통해 항종양 면역 반응을 강화하기 위한 방법 및 조성물 |
-
2018
- 2018-07-09 AU AU2018298673A patent/AU2018298673A1/en not_active Abandoned
- 2018-07-09 US US16/629,585 patent/US11447545B2/en active Active
- 2018-07-09 EP EP18743424.6A patent/EP3652207A1/en not_active Withdrawn
- 2018-07-09 BR BR112019027353-0A patent/BR112019027353A2/pt not_active IP Right Cessation
- 2018-07-09 CN CN201880046184.1A patent/CN111465614A/zh active Pending
- 2018-07-09 KR KR1020207001758A patent/KR20200026254A/ko not_active Withdrawn
- 2018-07-09 JP JP2020501379A patent/JP2020527144A/ja active Pending
- 2018-07-09 WO PCT/EP2018/068532 patent/WO2019011852A1/en not_active Ceased
- 2018-07-09 CA CA3066571A patent/CA3066571A1/en active Pending
-
2022
- 2022-09-19 US US17/933,133 patent/US20230085847A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527144A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2020526214A5 (https=) | ||
| HRP20220629T1 (hr) | Anti-cd73 antitijela i njihove upotrebe | |
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2021522801A5 (https=) | ||
| JP2020503891A5 (https=) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2019511212A5 (https=) | ||
| JP2017527275A5 (https=) | ||
| JP2020515239A5 (https=) | ||
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| JP2008516970A5 (https=) | ||
| JP2021526509A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2018508214A5 (https=) | ||
| JP2014039548A5 (https=) | ||
| JP2010532169A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2019513777A5 (https=) | ||
| JP2017513478A5 (https=) | ||
| JP2019533719A5 (https=) |